Euclidean Capital, a family office, is led by Jim Simons. He created Renaissance Technologies, arguably the world’s most successful quantitative investment firm, in 1982 and retired in 2010. Despite this, he continues to work at Renaissance and benefits from its finances. Jim Simons’ assets are managed and invested by Euclidean Capital, a New York-based firm. The hedge fund primarily invests in venture capital in the fields of biological science, public health, cybernetics, web technology, food, and biotechnology.
Insider Monkey highlights some of the 11 best pharma and biotech stocks to buy according to Jim Simons’ Euclidean Capital. Rubius Therapeutics, Inc. is the tenth greatest pharma and biotech company to purchase. The smart money is taking notice of the company, with 11 hedge funds reporting ownership positions in the first quarter. Vir Biotechnology, Inc. is the tenth best pharma and biotech stock to buy. Vir Biotechnology stock has returned more than 39% to investors so far this year. The ninth best pharma and biotech stock to purchase is Beam Therapeutics Inc. According to Jim Simons’ Euclidean Capital, Beam shares have increased in value by 339.99 percent in the last year. Constellation Pharmaceuticals, Inc. is ranked eighth among the top ten pharmaceutical and biotechnology stocks to invest in. Euclidean Capital, which is owned by Jim Simons, holds 554,325 shares of Constellation for $12.97 million. RAPT Therapeutics, Inc. is an immunology-based biopharmaceutical business in clinical development. Jim Simons’ Euclidean Capital named the business seventh among the top ten pharma and biotech stocks to purchase. For more details, click 11 Best Pharma and Biotech Stocks to Buy.